Literature DB >> 1933850

p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.

Y Yamada1, T Yoshida, K Hayashi, T Sekiya, J Yokota, S Hirohashi, K Nakatani, H Nakano, T Sugimura, M Terada.   

Abstract

Structural alterations of the p53 gene were investigated in tissue specimens of gastric and cervical cancers and in cell lines of gastric, esophageal, and cervical cancers, by polymerase chain reaction-single-strand conformation polymorphism analysis. Two of the four gastric cancer metastases and four of the eight cell lines originally established from gastric cancer metastases were found to have p53 gene alterations in the exon 5 to 11 region; point mutations and amino acid replacements were detected in a liver and an ovary metastasis at exon 7, in the TMK1 and MKN1 cell lines at exon 5, and in the OKAJIMA cell line at exon 10. The normal allele was not found in these cell lines. In the KATO-III cell line, gross deletion and rearrangement of the p53 gene were noted. However, no p53 mutations were identified in 19 primary lesions of gastric cancer, suggesting that the p53 gene abnormality preferentially occurs in the advanced stages of gastric cancer. In contrast to the gastric cancer, none of the 13 esophageal cancer cell lines, including two cell lines established from metastases, and none of the four cervical cancer cell lines showed any aberration in exons 5 to 11 of the p53 gene. During the course of the study, a novel polymorphism in intron 7 of the p53 gene was found, which can be recognized by restriction enzyme digestions of the polymerase chain reaction product.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933850

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Adenocarcinoma of the stomach: a review.

Authors:  James M McLoughlin
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

2.  PCAF acts as a gastric cancer suppressor through a novel PCAF-p16-CDK4 axis.

Authors:  Hong-Jun Fei; Li-Dong Zu; Jun Wu; Xiao-Shu Jiang; Jing-Long Wang; Y Eugene Chin; Guo-Hui Fu
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 3.  Molecular biology and gastric carcinoma.

Authors:  P A Wright; G T Williams
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

4.  TP53 gene mutations in gastric carcinoma detected by polymerase chain reaction/single-strand conformation polymorphism analysis of archival material.

Authors:  E D'Andrea; R Baffa; C Menin; M Montagna; M Rugge; L Chieco-Bianchi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  p53 alteration in gastric precancerous lesions.

Authors:  Y H Shiao; M Rugge; P Correa; H P Lehmann; W D Scheer
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

6.  p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.

Authors:  B G Schneider; S G Hilsenbeck; C H Hensel; V Pekkel; C H Shelton; H A Rodríguez-Martínez; M E Gutiérrez-Díaz; D R Pulitzer; D C Allred
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 7.  Multimodality treatment of cancer arising from Barrett's epithelium.

Authors:  J A Roth
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

8.  Analysis of p53 mutations and Helicobacter pylori infection in human and animal models.

Authors:  Kazunari Murakami; Toshio Fujioka; Masaaki Kodama; Shoji Honda; Tadayoshi Okimoto; Touta Oda; Akira Nishizono; Ryugo Sato; Toshihiro Kubota; Jiro Kagawa; Masaru Nasu
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

9.  Recombination and its roles in DNA repair, cellular immortalization and cancer.

Authors:  M A Shammas; R J Shmookler Reis
Journal:  Age (Omaha)       Date:  1999-04

10.  Detection of p53 overexpression in routinely paraffin-embedded tissue of human carcinomas using a novel target unmasking fluid.

Authors:  F M van den Berg; I O Baas; M M Polak; G J Offerhaus
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.